ITEM 5. OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated February 17, 2000.

                    MEDIMMUNE'S BOARD OF DIRECTORS AUTHORIZES
                            THREE-FOR-ONE STOCK SPLIT

Gaithersburg,  MD,  February 17, 2000 -- MedImmune,  Inc.  (Nasdaq:  MEDI) today
announced that its Board of Directors has declared a three-for-one  split of the
company's common stock, payable in the form of a 200-percent stock dividend. The
stock split is contingent  upon  shareholder  approval to increase the number of
authorized  shares of common stock from  120,000,000 to  320,000,000,  an action
that will be voted on at the Annual Meeting of  Shareholders on May 18, 2000. If
approved,  stockholders  will receive two additional shares for every share they
own as of the close of business on May 18,  2000.  Distribution  of shares would
occur  on or  about  June 2,  2000.  As of  December  31,  1999,  MedImmune  had
approximately 67.9 million shares of common stock outstanding.

"MedImmune  continues  to  believe  that  an  expanding  shareholder  base is an
essential  element  of  sustained  corporate  growth,"  commented  Dr.  Wayne T.
Hockmeyer,  chairman  and chief  executive  officer.  "We have seen  significant
growth in shareholder  value since our previous stock split,  and hope that this
split will make it possible  for many more people to be a part of the  continued
growth of both the company and the biotechnology industry."

MedImmune,   Inc.  is  a  fully  integrated  biotechnology  company  focused  on
developing  and marketing  products that address  medical needs in areas such as
infectious disease, immune regulation and cancer. Headquartered in Gaithersburg,
Maryland,  MedImmune has  manufacturing  facilities  in Frederick,  Maryland and
Nijmegen,  The  Netherlands,  and an oncology  subsidiary in West  Conshohocken,
Pennsylvania.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
company's filings with the U.S.  Securities and Exchange  Commission.  MedImmune
cautions that RSV disease occurs primarily during the winter months; the company
believes its operating results will reflect that seasonality for the foreseeable
future.  The company is also developing  several  products for potential  future
marketing. There can be no assurance that such development efforts will succeed,
that such products will receive required  regulatory  clearance or that, even if
such regulatory clearance were received,  such products would ultimately achieve
commercial success.
<PAGE>


                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                   MEDIMMUNE, INC.
                                   ---------------
                                   (Registrant)

February 25, 2000
By:
                                   /s/David M. Mott
                                   ----------------
                                   David M. Mott, Vice Chairman and
                                   Chief Financial Officer
[{"type": "8-K", "sequence": "1", "description": "MEDIMMUNE ANNOUNCES THREE-FOR-ONE STOCK SPLIT", "secsgml_size_bytes": 3562}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "562100"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
ITEM 5. OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated February 17, 2000.

                    MEDIMMUNE'S BOARD OF DIRECTORS AUTHORIZES
                            THREE-FOR-ONE STOCK SPLIT

Gaithersburg,  MD,  February 17, 2000 -- MedImmune,  Inc.  (Nasdaq:  MEDI) today
announced that its Board of Directors has declared a three-for-one  split of the
company's common stock, payable in the form of a 200-percent stock dividend. The
stock split is contingent  upon  shareholder  approval to increase the number of
authorized  shares of common stock from  120,000,000 to  320,000,000,  an action
that will be voted on at the Annual Meeting of  Shareholders on May 18, 2000. If
approved,  stockholders  will receive two additional shares for every share they
own as of the close of business on May 18,  2000.  Distribution  of shares would
occur  on or  about  June 2,  2000.  As of  December  31,  1999,  MedImmune  had
approximately 67.9 million shares of common stock outstanding.

"MedImmune  continues  to  believe  that  an  expanding  shareholder  base is an
essential  element  of  sustained  corporate  growth,"  commented  Dr.  Wayne T.
Hockmeyer,  chairman  and chief  executive  officer.  "We have seen  significant
growth in shareholder  value since our previous stock split,  and hope that this
split will make it possible  for many more people to be a part of the  continued
growth of both the company and the biotechnology industry."

MedImmune,   Inc.  is  a  fully  integrated  biotechnology  company  focused  on
developing  and marketing  products that address  medical needs in areas such as
infectious disease, immune regulation and cancer. Headquartered in Gaithersburg,
Maryland,  MedImmune has  manufacturing  facilities  in Frederick,  Maryland and
Nijmegen,  The  Netherlands,  and an oncology  subsidiary in West  Conshohocken,
Pennsylvania.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
company's filings with the U.S.  Securities and Exchange  Commission.  MedImmune
cautions that RSV disease occurs primarily during the winter months; the company
believes its operating results will reflect that seasonality for the foreseeable
future.  The company is also developing  several  products for potential  future
marketing. There can be no assurance that such development efforts will succeed,
that such products will receive required  regulatory  clearance or that, even if
such regulatory clearance were received,  such products would ultimately achieve
commercial success.
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                   MEDIMMUNE, INC.
                                   ---------------
                                   (Registrant)

February 25, 2000
By:
                                   /s/David M. Mott
                                   ----------------
                                   David M. Mott, Vice Chairman and
                                   Chief Financial Officer